ATE256138T1 - 9-oximsilyl erythromycin a derivate - Google Patents

9-oximsilyl erythromycin a derivate

Info

Publication number
ATE256138T1
ATE256138T1 AT97905826T AT97905826T ATE256138T1 AT E256138 T1 ATE256138 T1 AT E256138T1 AT 97905826 T AT97905826 T AT 97905826T AT 97905826 T AT97905826 T AT 97905826T AT E256138 T1 ATE256138 T1 AT E256138T1
Authority
AT
Austria
Prior art keywords
derivatives
oximesilyl
erythromycin
oximesilyl erythromycin
alkylerythromycin
Prior art date
Application number
AT97905826T
Other languages
German (de)
English (en)
Inventor
Yi-Yin Ku
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24510750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE256138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE256138T1 publication Critical patent/ATE256138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97905826T 1996-04-02 1997-02-06 9-oximsilyl erythromycin a derivate ATE256138T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/626,524 US5837829A (en) 1996-04-02 1996-04-02 9-oximesilyl erythromycin a derivatives
PCT/US1997/001955 WO1997036913A1 (en) 1996-04-02 1997-02-06 9-oximesilyl erythromycin a derivatives

Publications (1)

Publication Number Publication Date
ATE256138T1 true ATE256138T1 (de) 2003-12-15

Family

ID=24510750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905826T ATE256138T1 (de) 1996-04-02 1997-02-06 9-oximsilyl erythromycin a derivate

Country Status (10)

Country Link
US (1) US5837829A (enExample)
EP (1) EP0891371B1 (enExample)
JP (2) JP2000507574A (enExample)
AT (1) ATE256138T1 (enExample)
CA (1) CA2250771C (enExample)
DE (1) DE69726714T2 (enExample)
DK (1) DK0891371T3 (enExample)
ES (1) ES2212808T3 (enExample)
PT (1) PT891371E (enExample)
WO (1) WO1997036913A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT915899E (pt) 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO1999032500A2 (en) * 1997-12-22 1999-07-01 Biochemie S.A. Intermediates in macrolide production
KR100283990B1 (ko) * 1998-12-29 2001-03-02 민경윤 에리스로마이신 a 유도체 및 그의 제조방법
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
CN1193036C (zh) * 2000-03-15 2005-03-16 韩美药品工业株式会社 制备甲红霉素－克拉霉素ⅱ型晶体的方法
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
EP1648418A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) * 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법

Also Published As

Publication number Publication date
EP0891371B1 (en) 2003-12-10
US5837829A (en) 1998-11-17
PT891371E (pt) 2004-04-30
CA2250771A1 (en) 1997-10-09
DE69726714D1 (en) 2004-01-22
ES2212808T3 (es) 2004-08-01
JP2007224035A (ja) 2007-09-06
DK0891371T3 (da) 2004-04-13
JP2000507574A (ja) 2000-06-20
EP0891371A1 (en) 1999-01-20
CA2250771C (en) 2006-05-02
DE69726714T2 (de) 2004-10-07
WO1997036913A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
DE69726714T2 (de) 9-oximsilyl erythromycin a derivate
DE69811120D1 (de) 6-o-alkyl erythronolid-b derivate
FI872093L (fi) Haordmetall med bindemedelsfasgradient och foerfarande foer framstaellning av den.
NO903656D0 (no) Fremgangsmaate for fremstilling av 17beta-acyl-4-aza-5alfa-androst-1-en-3-oner.
FI931427A0 (fi) Ny onkofetal gen, genprodukt och anvaendningen daerav
GR890100033A (el) Μέ?οδος παρασκευής διδεοξυδιδευδροκαρβοκυκλικών νουκλεοσιδών.
NO872831L (no) FremgangsmŸte for fremstilling av nitrofuranderivater.
EE9900196A (et) Bensüüleetrite valmistamise protsess
FI882397L (fi) Vaccin och framstaellningsfoerfarande.
NO913745L (no) Fremgangsmaate for fremstilling av 1,3-benzoksazinderivater
NO901070D0 (no) Fremgangsmaate for fremstilling av tieno-triazolo-diazepin-derivater.
TR23145A (tr) Diflufenican kullanan herbisidal usul
NO901832D0 (no) Fremgangsmaate for fremstilling av polyketon.
NO901071D0 (no) Fremgangsmaate for fremstilling av tieno-triazolo-diazepin-derivater.
NO900969D0 (no) Fremgangsmaate for fremstilling av anilin-derivat.
NO961429D0 (no) Fremgangsmåte for fremstilling av kinolonholdige, orale preparater
DE69007317D1 (de) Difluoroalkylcyclohexyl-benzonitril Derivate.
FI971964L (fi) Menetelmä 1-halo-3-trialkyylisilasnyylibentseenijohdannaisten valmistamiseksi
NO903196D0 (no) Fremgangsmaate for fremstilling av 2-diazo-3-trisubstituerte silyloksy-3-butenoater.
NO167387C (no) Fremgangsmaate for fremstilling av 2-guanidinothiazolderivat.
NO890216D0 (no) Fremgangsmaate for revitalisering av forstkulturer.
FI20040505A7 (fi) Menetelmä 1,3-dihydro-6-hydroksi-2H-indol-2-oni-johdannaisten valmistamiseksi
UA25100A (uk) Припрацювальhа суміш
DK136386D0 (da) Hoejttaler, navnlig bashoejttaler
FI874249A0 (fi) Foerfarande foer framstaellning av 3-dimetylamino-7-metyl-1,2,4-bensotriazin-1-oxid och azapropazon.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0891371

Country of ref document: EP

REN Ceased due to non-payment of the annual fee